摘要
目的探讨滋肾化瘀汤应用在子宫宫腔手术后宫腔粘连(IUA)的临床疗效以及对转录调节因子叉头框F2(FoxF2)、转化生长因子-β1(TGF-β1)表达的影响。方法选择2018年1月至2019年3月行宫腔操作的患者68例,根据住院号随机分为试验组和对照组,每组34例,试验组采用滋肾化瘀汤预防宫腔粘连,对照组采用雌激素预防宫腔粘连。随访2组患者治疗前后中医证候改善情况;治疗后月经恢复情况及子宫内膜厚度;比较宫腔镜查看粘连分度、例数及总发生率;比较2组患者血清FoxF2、TGF-β1的阳性例数表达状况。结果治疗后试验组患者中医证候改善、月经恢复、子宫内膜厚度、宫腔再发粘连与对照组差异有统计学意义(P<0.05);治疗后2组患者的FoxF2、TGF-β1阳性例数明显低于治疗前,且试验组例数明显少于对照组,差异有统计学意义(P<0.05)。结论滋肾化瘀汤在预防宫腔术后腔内粘连、促进子宫内膜功能恢复、抑制FoxF2、TGF-β1的表达等方面具有明显优势,值得临床应用。
Objective To investigate the clinical efficacy of Zishenhuayu decoction in treatment of intrauterine adhesions(IUA)after uterine cavity surgery,and to observe its effects on the expressions of FoxF2(transcriptional regulator F2)and TGF-β1(transforming growth factor-1).Methods A total of 68 patients who underwent uterine cavity surgery in our hospital from January 20 to March 2019 were enrolled in the study,who were randomly divided into experimental group(n=34)and the control group(n=34)according to the hospitalization number.The patients in experimental group were treated by Zishenhuayu decoction to prevent IUA,and the patients in control group were treated by estrogen to prevent IUA.The improvement status of TCM syndromes before and after treatment was obseved by the same TCM doctor.And the menstrual recovery and endometrial thickness after treatment,adhesion index,number of cases and total incidence,and the expression levels of serum FoxF2 and TGF-β1 were observed and compared between the two groups.Results After treatment,the TCM syndrome improvement,menstrual recovery,endometrial thickness,and recurrence of uterine cavity were significantly improved in both groups,as compared with those before treatment(P<0.05).Moreover the expression levels of FoxF2 and TGF-β1 were significantly lower than those before treatment(P<0.05).Conclusion Zishenhuayu decoction has obvious advantages in preventing IUA after uterine cavity surgery,promoting endometrial function recovery,inhibiting the expression of FoxF2 and TGF-β1,therefor,it is worthy of clinical application.
作者
梁红霞
许建多
毛丽梅
杜晓静
来于
LIANG Hongxia;XU Jianduo;MAO Limei(Shijiazhuang Hospital for Maternal and Child Health,Hebei, Shijiazhuang 050000, China)
出处
《河北医药》
CAS
2020年第3期349-352,共4页
Hebei Medical Journal
基金
河北省中医药管理局科研计划项目(编号:2018245)
